Alessandra Gonnelli, Marine Gerbé de Thoré, Maria Laura Ermini, Valentina Frusca, Agata Zamborlin, Nicolas Signolle, Olivia Bawa, Céline Clémenson, Lydia Meziani, Paul Bergeron, Ismail El-Azrak, Patrizia Sarogni, Enrico Mugnaioli, Noemi Giannini, Giuliana Drava, Eric Deutsch, Fabiola Paiar, Michele Mondini, Valerio Voliani
Cisplatin chemoradiotherapy (CRT) is the established standard of care for managing HPV+ head/neck carcinoma. The typically young patients may suffer serious and long-time side effects caused by the treatment, such as dysphagia, and hearing loss. Thus, ensuring a satisfactory post-treatment quality of life is paramount. One potential replacing approach to the classical CRT involves the combination of standard-dose radiotherapy and radiosensitizers such as noble metal nanoparticles (NPs). However, several concerns about size, shape and biocompatibility limit the translation of metal nanomaterials to the clinical practice...
May 18, 2024: Advanced Materials